Intravitreal Infliximab ( DrugBank: Infliximab )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 56 | Behcet disease | 1 |
56. Behcet disease
Clinical trials : 76 / Drugs : 110 - (DrugBank : 32) / Drug target genes : 36 - Drug target pathways : 116
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02620618 (ClinicalTrials.gov) | January 2013 | 26/11/2015 | Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study | Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study | Behçet's Disease;Uveitis | Drug: Intravitreal Infliximab | Cairo University | NULL | Completed | N/A | N/A | Both | 20 | Phase 1/Phase 2 | NULL |